Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma
Background: Concurrent treatment with BRAF inhibitors and palliative radiation therapy (RT) could be associated with increased toxicity, especially skin toxicity. Current Eastern Cooperative Oncology Group (ECOG) consensus guideline recommend ceasing BRAF inhibitors during RT. There is a lack of dat...
Main Authors: | Wei Wang, Jessica Louise Smith, Matteo Salvatore Carlino, Bryan Burmeister, Mark Blayne Pinkham, Gerald Blaise Fogarty, David Robert Harry Christie, Vanessa Estall, Mark Shackleton, Arthur Clements, Rory Wolfe, Le Thi Phuong Thao, Elizabeth Jane Paton, Victoria Steel, Narelle Catherine Williams |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-09-01
|
Series: | Clinical and Translational Radiation Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405630821000744 |
Similar Items
-
Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
by: Weart TC, et al.
Published: (2018-04-01) -
Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
by: David Balakirouchenane, et al.
Published: (2020-04-01) -
Dabrafenib and Trametinib prolong coagulation through the inhibition of tissue factor in BRAFv600e mutated melanoma cells in vitro
by: Cristian Scatena, et al.
Published: (2019-08-01) -
Ocular toxicity due to Trametinib and Dabrafenib
by: Stephanie Sarny, et al.
Published: (2017-08-01) -
BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy
by: Jan Dörrie, et al.
Published: (2018-01-01)